Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target for Fever-Tree on Molson Coors partnership

(Sharecast News) - Berenberg has hiked its target price for tonic maker Fever-Tree on the back of the tonic maker's partnership with Molson Coors, which it said appears "highly attractive". Fever-Tree announced last week that it had entered into a strategic partnership with Molson Coors to drive the next stage of growth in the US.

The deal, which will see the American brewing giant take an 8.5% stake in the business, includes the exclusive sales, distribution and production of the Fever-Tree brand in the US - a market where it has been operating since 2008.

Berenberg labelled the tie-up between the two companies "a strong match", given Molson Coors' highly aligned distribution network.

"The partnership will allow Fever-Tree's products to tap into a vast distribution network within the US, supported by increased marketing resources, which is to yield growth acceleration and margin expansion for Fever-Tree," the broker said.

"In addition, we are positive about the amount of cash that the partnership will free up for Fever-Tree, which we think will translate to shareholder returns or alternatively, be invested in the company's growth."

Nevertheless, Berenberg still decided to keep a 'hold' rating on the stock, citing "operational uncertainty and continued subdued demand in Fever-Tree's other key markets".

Fever-Tree shares were up 1.1% at 739.3p by 1031 GMT, and now stand 10% higher over the year-to-date following a positive reaction to last week's deal.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.